Minaprine dihydrochloride | CAS #25905-77-5 (2HCl)

MedKoo Cat#: 318276 | Name: Minaprine dihydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Minaprine is an antidepressant. A study found that it acts as a reversible inhibitor of MAO-A (RIMA) in rats. In a study it has also been found to weakly inhibit acetylcholinesterase in rat brain (striatum) homogenates.

Chemical Structure

Minaprine dihydrochloride

CAS#25953-17-7 (2HCl)

Theoretical Analysis

MedKoo Cat#: 318276

Name: Minaprine dihydrochloride

CAS#: 25953-17-7 (2HCl)

Chemical Formula: C17H24Cl2N4O

Exact Mass: 0.0000

Molecular Weight: 371.31

Elemental Analysis: C, 54.99; H, 6.52; Cl, 19.09; N, 15.09; O, 4.31

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

25953-17-7 (2HCl) 25905-77-5 (free base)

Synonym

Minaprine dihydrochloride, Cantor, Minaprina, Minaprinum, Brantur, Agr 1240

IUPAC/Chemical Name

4-methyl-N-(2-morpholinoethyl)-6-phenylpyridazin-3-amine dihydrochloride

InChi Key

GNUCGROXDZMCJI-UHFFFAOYSA-N

InChi Code

InChI=1S/C17H22N4O.2ClH/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21;;/h2-6,13H,7-12H2,1H3,(H,18,20);2*1H

SMILES Code

CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3.Cl.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Minaprine dihydrochloride is a reversible inhibitor of MAO-A.

In vitro activity:

The antidepressant, minaprine, did not modify the basal release of [3H]ACh but it antagonised the inhibitory effect of TFMPP on the K+-evoked release. The maximal reversal was found at 0.3 microM minaprine. These results suggest that minaprine interacts with heterologous presynaptic 5-HT1B receptors. Reference: Eur J Pharmacol. 1989 Sep 1;168(1):87-92. https://pubmed.ncbi.nlm.nih.gov/2583235/

In vivo activity:

The present experiments show that either repeated stress (120 min restraint daily for 10 consecutive days) or subchronic treatment with the antidepressant minaprine (5 mg/kg daily for 10 consecutive days) significantly reduced the inhibitory effect of 120 min of restraint on climbing, a behavioral response dependent on mesolimbic DA functioning. Chronic stressful experience (13 days of food restriction) and repeated amphetamine (2.5 mg/kg daily for 10 consecutive days) were as effective as subchronic minaprine in reducing immobility in the Porsolt's swimming test. However, whilst both stress and amphetamine enhanced struggling, minaprine promoted swimming. Reference: Psychopharmacology (Berl). 1995 Sep;121(1):73-80. https://pubmed.ncbi.nlm.nih.gov/8539343/

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	269.32
	Water	100.0	269.32

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 371.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Bolanos F, Fillion G. Minaprine antagonises the serotonergic inhibitory effect of trifluoromethylphenylpiperazine (TFMPP) on acetylcholine release. Eur J Pharmacol. 1989 Sep 1;168(1):87-92. doi: 10.1016/0014-2999(89)90636-5. PMID: 2583235. 2. Cabib S, Zocchi A, Puglisi-Allegra S. A comparison of the behavioral effects of minaprine, amphetamine and stress. Psychopharmacology (Berl). 1995 Sep;121(1):73-80. doi: 10.1007/BF02245593. PMID: 8539343. 3. Piao Y, Mineshita S, Kuroiwa T, Koike Y. Prevention by minaprine of ischemic neuronal damage and memory impairment in Mongolian gerbils. Nihon Shinkei Seishin Yakurigaku Zasshi. 1995 Apr;15(2):157-63. PMID: 7796320.

In vitro protocol:

In vivo protocol:

1. Cabib S, Zocchi A, Puglisi-Allegra S. A comparison of the behavioral effects of minaprine, amphetamine and stress. Psychopharmacology (Berl). 1995 Sep;121(1):73-80. doi: 10.1007/BF02245593. PMID: 8539343. 2. Piao Y, Mineshita S, Kuroiwa T, Koike Y. Prevention by minaprine of ischemic neuronal damage and memory impairment in Mongolian gerbils. Nihon Shinkei Seishin Yakurigaku Zasshi. 1995 Apr;15(2):157-63. PMID: 7796320.

1: Edwards JG, Dinan TG, Waller DG, Greentree SG. Double-blind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline. Br J Clin Pharmacol. 1996 Oct;42(4):491-8. PubMed PMID: 8904622; PubMed Central PMCID: PMC2042690. 2: Jouglard J, Perringue C, Goujard J, Servetti A, David JM. [Evaluation by poison control centers of minaprine from the modification of tablet dosages]. Therapie. 1996 Sep-Oct;51(5):582-5. French. PubMed PMID: 9138401. 3: Salzmann E, Robin JL. Multicentric double-blind study comparing efficacy and safety of minaprine and imipramine in dysthymic disorders. Neuropsychobiology. 1995;31(2):68-75. PubMed PMID: 7760988. 4: Imperato A, Obinu MC, Cabib S, Cestari V, Puglisi-Allegra S. Effects of subchronic minaprine on dopamine release in the ventral striatum and on immobility in the forced swimming test. Neurosci Lett. 1994 Jan 17;166(1):69-72. PubMed PMID: 8190361. 5: Puglisi-Allegra S, Cabib S, Cestari V, Castellano C. Post-training minaprine enhances memory storage in mice: involvement of D1 and D2 dopamine receptors. Psychopharmacology (Berl). 1994 Jan;113(3-4):476-80. PubMed PMID: 7862862. 6: Kinirons MT, Jackson SH, Kalra L, Trevit RT, Swift CG. Computerised psychomotor performance testing: a comparative study of the single dose pharmacodynamics of minaprine and amitriptyline in young and elderly subjects. Br J Clin Pharmacol. 1993 Oct;36(4):376-9. PubMed PMID: 12959320; PubMed Central PMCID: PMC1364695. 7: Kodama K, Shibata S, Ueki S. Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn J Pharmacol. 1992 Sep;60(1):33-8. PubMed PMID: 1361012. 8: Ambrogi Lorenzini C, Baldi E, Bucherelli C, Tassoni G. Minaprine cancels scopolamine effects on the rat's acquisition of passive avoidance responses in two multitrial paradigms. Pharmacol Biochem Behav. 1992 Apr;41(4):715-8. PubMed PMID: 1594638. 9: Marre F, Fabre G, Lacarelle B, Bourrie M, Catalin J, Berger Y, Rahmani R, Cano JP. Involvement of the cytochrome P-450IID subfamily in minaprine 4-hydroxylation by human hepatic microsomes. Drug Metab Dispos. 1992 Mar-Apr;20(2):316-21. PubMed PMID: 1352227. 10: Davi H, Bonnet JM, Berger Y. Disposition of minaprine in animals and in human extensive and limited debrisoquine hydroxylators. Xenobiotica. 1992 Feb;22(2):171-84. PubMed PMID: 1632106. 11: Chaki S, Muramatsu M, Otomo S. Blockade of voltage-dependent 42K efflux from rat brain synaptosome by minaprine and tetrahydroaminoacridine. Life Sci. 1991;48(25):2383-90. PubMed PMID: 2046464. 12: Okuyama S, Shimamura-Harada H, Karasawa Y, Kawashima K, Araki H, Kimura M, Otomo S, Aihara H. Protective effects of minaprine in infarction produced by occluding middle cerebral artery in stroke-prone spontaneously hypertensive rats. Gen Pharmacol. 1991;22(1):143-50. PubMed PMID: 1675616. 13: Chaki S, Usuki-Ito C, Muramatsu M, Otomo S. Differentiation of the active site of minaprine from that of phencyclidine in rat hippocampus. Res Commun Chem Pathol Pharmacol. 1990 Jul;69(1):85-98. PubMed PMID: 1977191. 14: Muramatsu M, Usuki-Ito C, Aihara H. [(3)H]Minaprine binding to membrane preparation from rat brain. Neurochem Int. 1990;17(1):67-75. PubMed PMID: 20504604. 15: Muramatsu M, Chaki S, Usuki-Ito C, Aihara H. Attenuation of serotonin-induced suppression of [(3)H]acetylcholine release from rat cerebral cortex by minaprine: Possible involvement of the serotonin-2 receptor and K(+) channel. Neurochem Int. 1990;16(3):301-7. PubMed PMID: 20504572. 16: Yamamoto T, Yatsugi S, Ohno M, Furuya Y, Kitajima I, Ueki S. Minaprine improves impairment of working memory induced by scopolamine and cerebral ischemia in rats. Psychopharmacology (Berl). 1990;100(3):316-22. PubMed PMID: 2315427. 17: Bolanos F, Fillion G. Minaprine antagonises the serotonergic inhibitory effect of trifluoromethylphenylpiperazine (TFMPP) on acetylcholine release. Eur J Pharmacol. 1989 Sep 1;168(1):87-92. PubMed PMID: 2583235. 18: Okuyama S, Aihara H. Effect of minaprine on electrical activity of the rat hippocampus in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1989 Jul;340(1):1-5. PubMed PMID: 2797211. 19: Wheatley D. Minaprine: an anticholinergic-free antidepressant? Results of a controlled trial of mianserin. Br J Psychiatry. 1989 Jul;155:106-7. PubMed PMID: 2690999. 20: Isel F, Mandel P. Alterations of serotonin neurotransmission and inhibition of mouse-killing behavior: III. Effects of minaprine, CM 30366 and SR 95191. Pharmacol Biochem Behav. 1989 Jul;33(3):655-62. PubMed PMID: 2531423.